{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:48:19Z","timestamp":1761155299107},"reference-count":29,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.jviromet.2009.07.023","type":"journal-article","created":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T08:57:59Z","timestamp":1249376279000},"page":"101-108","source":"Crossref","is-referenced-by-count":15,"title":["Clinical cut-offs for HIV-1 phenotypic resistance estimates: Update based on recent pivotal clinical trial data and a revised approach to viral mixtures"],"prefix":"10.1016","volume":"162","author":[{"given":"Bart","family":"Winters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Van Craenenbroeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen","family":"Van der Borght","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Lecocq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Villacian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Bacheler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2009.07.023_bib1","series-title":"Proceedings of the 5th European HIV Drug Resistance Workshop","article-title":"Clinically relevant phenotypic resistance and cross-resistance to tipranavir among recent routine clinical isolates","author":"Bacheler","year":"2006"},{"key":"10.1016\/j.jviromet.2009.07.023_bib2","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Virco\u00aeTYPE clinical cut-offs for TMC114","author":"Bacheler","year":"2006"},{"key":"10.1016\/j.jviromet.2009.07.023_bib3","doi-asserted-by":"crossref","first-page":"F83","DOI":"10.1097\/00002030-200006160-00001","article-title":"A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy","volume":"14","author":"Baxter","year":"2000","journal-title":"Aids"},{"key":"10.1016\/j.jviromet.2009.07.023_bib4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/135965350400900420","article-title":"Clinically validated genotype analysis: guiding principles and statistical concerns","volume":"9","author":"Brun-Vezinet","year":"2004","journal-title":"Antivir. Ther."},{"issue":"3","key":"10.1016\/j.jviromet.2009.07.023_bib5","article-title":"Genotypic sensitivity score predicts HIV viral suppression among treatment experienced patients with advanced HIV disease receiving modified DOT","volume":"6","author":"Castor","year":"2004","journal-title":"MedGenMed"},{"key":"10.1016\/j.jviromet.2009.07.023_bib6","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir\u2013ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jviromet.2009.07.023_bib7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00002030-200203080-00009","article-title":"A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy","volume":"16","author":"Cohen","year":"2002","journal-title":"Aids"},{"key":"10.1016\/j.jviromet.2009.07.023_bib8","volume":"vol. 2009","author":"European AIDS Clinical Society","year":"2008"},{"key":"10.1016\/j.jviromet.2009.07.023_bib9","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1371\/journal.pctr.0010018","article-title":"A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study","volume":"1","author":"Hales","year":"2006","journal-title":"PLoS Clin. Trials"},{"key":"10.1016\/j.jviromet.2009.07.023_bib10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jviromet.2009.07.023_bib11","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1097\/00002030-200109070-00010","article-title":"World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing","volume":"15","author":"Harrigan","year":"2001","journal-title":"Aids"},{"key":"10.1016\/j.jviromet.2009.07.023_bib12","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1002\/1097-0258(20001215)19:23<3171::AID-SIM619>3.0.CO;2-T","article-title":"Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials","volume":"19","author":"Hughes","year":"2000","journal-title":"Stat. Med."},{"key":"10.1016\/j.jviromet.2009.07.023_bib13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/00002030-200304110-00007","article-title":"Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs","volume":"17","author":"Katzenstein","year":"2003","journal-title":"Aids"},{"key":"10.1016\/j.jviromet.2009.07.023_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Lazzarin","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jviromet.2009.07.023_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"Efficacy and safety of darunavir-ritonavir compared with that of lopinavir\u2013ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jviromet.2009.07.023_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)61047-2","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jviromet.2009.07.023_bib17","series-title":"Presented at the 7th Conference on Retroviruses and Opportunistic Infections [abstract 786]","article-title":"Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral thereapy (ART) in heavily experienced patients","author":"Melnick","year":"2000"},{"key":"10.1016\/j.jviromet.2009.07.023_bib18","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/381784","article-title":"Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients","volume":"189","author":"Miller","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jviromet.2009.07.023_bib19","series-title":"Applied Linear Statistical Models: Regression, Analysis of Variance, and Experimental Designs","author":"Neter","year":"1990"},{"key":"10.1016\/j.jviromet.2009.07.023_bib20","author":"Panel on Antiretroviral Guidelines for Adult Adolescents (D.o.H.a.H.S.)"},{"key":"10.1016\/j.jviromet.2009.07.023_bib21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1128\/AAC.48.2.437-443.2004","article-title":"Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1","volume":"48","author":"Parkin","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2009.07.023_bib22","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1086\/422692","article-title":"Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects","volume":"190","author":"Swanstrom","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jviromet.2009.07.023_bib23","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jviromet.2009.07.023_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2007.05.009","article-title":"Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling","author":"Vermeiren","year":"2007","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jviromet.2009.07.023_bib25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1086\/381266","article-title":"Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial","volume":"38","author":"Wegner","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jviromet.2009.07.023_bib26","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/01.aids.0000181009.77632.36","article-title":"The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals","volume":"19","author":"Winston","year":"2005","journal-title":"Aids"},{"key":"10.1016\/j.jviromet.2009.07.023_bib27","series-title":"Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections","article-title":"Development of vircoTYPE HIV-1 resistance analysis, including clinical cutoffs, for ritonavir-boosted atazanavir and fosamprenavir","author":"Winters","year":"2007"},{"key":"10.1016\/j.jviromet.2009.07.023_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0b013e31816d9bf4","article-title":"Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data","author":"Winters","year":"2008","journal-title":"J. Acquir. Immune Deficiency Syndrome"},{"key":"10.1016\/j.jviromet.2009.07.023_bib29","series-title":"Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections","article-title":"Development of vircoTYPE HIV-1 resistance analysis, including clinical cutoffs for TMC125, a new NNRTI","author":"Winters","year":"2008"}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093409003498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093409003498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T06:38:54Z","timestamp":1685083134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166093409003498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":29,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0166093409003498"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2009.07.023","relation":{},"ISSN":["0166-0934"],"issn-type":[{"value":"0166-0934","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}